{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:37:39Z","timestamp":1793839059774,"version":"4.6.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41379-021-00895-7","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T02:02:38Z","timestamp":1630375358000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"S1","title":["Pleural mesothelioma classification\u2014update and challenges"],"prefix":"10.1016","volume":"35","author":[{"given":"Sanja","family":"Dacic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-021-00895-7_bib1","unstructured":"Sauter, J. L., Bueno, R., Dacic, S., Gill, R. R., Husain, A. N. & Kadota K. et al. Diffuse Pleural Mesothelioma. WHO Classification of Tumors Editorial Board. 5th ed. 204\u2013219 (Lyon IARC Press, 2021)."},{"key":"10.1038\/s41379-021-00895-7_bib2","first-page":"151","article-title":"The concept of mesothelioma in situ: implications for diagnosis and histogenesis","volume":"9","author":"Whitaker","year":"1992","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ajcp\/110.3.397","article-title":"Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review","volume":"110","author":"Henderson","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/his.13468","article-title":"Malignant mesothelioma in situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"key":"10.1038\/s41379-021-00895-7_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00428-019-02674-x","article-title":"Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report","volume":"476","author":"Minami","year":"2020","journal-title":"Virchows Arch."},{"key":"10.1038\/s41379-021-00895-7_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"10.1038\/s41379-021-00895-7_bib8","doi-asserted-by":"crossref","unstructured":"Chevrier, M., Monaco, S. E., Jerome, J. A., Galateau-Salle, F., Churg, A. & Dacic, S. Testing for BAP1 loss and CDKN2A\/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol.128, 939\u201347 (2020).","DOI":"10.1002\/cncy.22326"},{"key":"10.1038\/s41379-021-00895-7_bib9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/dc.23837","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions","volume":"46","author":"Cozzi","year":"2018","journal-title":"Diagn. Cytopathol."},{"key":"10.1038\/s41379-021-00895-7_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"10.1038\/s41379-021-00895-7_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1038\/s41379-021-00895-7_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/PAP.0000000000000180","article-title":"Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples","volume":"25","author":"Monaco","year":"2018","journal-title":"Adv. Anat. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib14","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-021-00895-7_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J. Surg. Res."},{"key":"10.1038\/s41379-021-00895-7_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","article-title":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","volume":"86","author":"Mansfield","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.5858\/arpa.2017-0295-OA","article-title":"Reproducibility of malignant pleural mesothelioma histopathologic subtyping","volume":"142","author":"Brcic","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1038\/s41379-021-00895-7_bib19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib21","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal","volume":"13","author":"Pelosi","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1038\/s41379-021-00895-7_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1038\/s41379-021-00895-7_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1038\/s41379-021-00895-7_bib27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1038\/s41379-021-00895-7_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2020.09.002","article-title":"Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ","volume":"149","author":"Dacic","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1038\/s41379-021-00895-7_bib31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","article-title":"Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center","volume":"15","author":"Galateau Salle","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41379-019-0320-y","article-title":"Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas","volume":"33","author":"Dacic","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib34","doi-asserted-by":"crossref","unstructured":"Schulte, J. J., Chapel, D. B., Attanoos, R., Brcic, L., Burn, J. & Butnor K. J. et al. Comparison of nuclear grade, necrosis, and histologic subtype between biopsy and resection in pleural malignant mesothelioma. Am. J. Clin. Pathol.https:\/\/doi.org\/10.1093\/ajcp\/aqab054 (2021).","DOI":"10.1093\/ajcp\/aqab054"},{"key":"10.1038\/s41379-021-00895-7_bib35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/path.5551","article-title":"Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma","volume":"253","author":"De Rienzo","year":"2021","journal-title":"J. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib37","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.07.015","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2018.07.041","article-title":"Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic\/molecular analysis of malignant mesothelioma subtypes","volume":"124","author":"Churg","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2020.08.005","article-title":"The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas","volume":"105","author":"Prabhakaran","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/PAS.0000000000000825","article-title":"GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung","volume":"41","author":"Berg","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New INsights on Diagnostic Reproducibility of Biphasic Mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center","volume":"13","author":"Galateau Salle","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jclinpath-2012-201303","article-title":"Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib44","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","article-title":"Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial","volume":"361","author":"Maskell","year":"2003","journal-title":"Lancet."},{"key":"10.1038\/s41379-021-00895-7_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000443483","article-title":"CT scan-guided abrams' needle pleural biopsy versus ultrasound-assisted cutting needle pleural biopsy for diagnosis in patients with pleural effusion: a randomized, controlled trial","volume":"91","author":"Metintas","year":"2016","journal-title":"Respiration"},{"key":"10.1038\/s41379-021-00895-7_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1038\/s41379-021-00895-7_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1038\/s41379-021-00895-7_bib48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib49","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/PAS.0000000000001656","article-title":"Pediatric mesothelioma with ALK fusions: a molecular and pathologic study of 5 cases","volume":"45","author":"Argani","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jtho.2019.11.011","article-title":"Anaplastic lymphoma kinase gene rearrangement in children and young adults with mesothelioma","volume":"15","author":"Mian","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib53","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/PAS.0000000000000864","article-title":"A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions","volume":"41","author":"Desmeules","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1038\/s41379-021-00895-7_bib54","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/gcc.22068","article-title":"RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)","volume":"52","author":"Panagopoulos","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib55","doi-asserted-by":"crossref","first-page":"684025","DOI":"10.3389\/fonc.2021.684025","article-title":"Immune microenvironment and genetics in malignant pleural mesothelioma","volume":"11","author":"Wadowski","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1038\/s41379-021-00895-7_bib56","doi-asserted-by":"crossref","unstructured":"Napoli, F., Listi, A., Zambelli, V., Witel, G., Bironzo, P. & Papotti, M. et al. Pathological characterization of tumor immune microenvironment (TIME) in malignant pleural mesothelioma. Cancers13 (2021).","DOI":"10.3390\/cancers13112564"},{"key":"10.1038\/s41379-021-00895-7_bib57","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study","volume":"10","author":"Brcic","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1038\/s41379-021-00895-7_bib58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib59","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1038\/s41379-021-00895-7_bib60","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","article-title":"Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma","volume":"46","author":"Sobhani","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1038\/s41379-021-00895-7_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum. Pathol."}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00895-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00895-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00895-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:27:36Z","timestamp":1760228856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":61,"alternative-id":["S0893395222000710"],"URL":"https:\/\/doi.org\/10.1038\/s41379-021-00895-7","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleural mesothelioma classification\u2014update and challenges","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-021-00895-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}